• Vaccine Name: Salmonella Typhimurium clpP mutant vaccine
• Target Pathogen: Salmonella spp.
• Target Disease: Salmonellosis
• Product Name: CS2007
• Vaccine Ontology ID: VO_0002872
• Type: Live, attenuated vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Mouse
• clpP from S. typhimurium str. LT2 gene engineering:
  • Type: Gene mutation
  • Description: This clpP mutant is from Salmonella Typhimurium (Matsui et al., 2003).
  • Detailed Gene Information: Click Here.
• Immunization Route: Oral immunization

Mouse Response

• Persistence: A clpP mutant (CS2007) causes hyperflagellation. These hyperflagellated bacteria are attenuated in mice (Matsui et al., 2003).
• Efficacy: A clpP mutant elicited protection in mice from challenge with wild type S. typhimurium (Matsui et al., 2003).
• Host IgA response
  • Description: Significant increases of lipopolysaccharide-specific immunoglobulin G (IgG) and secretory IgA were detected at week 4 and maintained until at least week 12 after inoculation in serum and bile. Testing before week 4 revealed undetectable or extremely low levels of antibodies, meaning the presence of much higher levels after week 4 were the result of upregulation of IgG and IgA (Matsui et al., 2003).
  • Detailed Gene Information: Click Here.
• Host IgG response
  • Description: Significant increases of lipopolysaccharide-specific immunoglobulin G (IgG) and secretory IgA were detected at week 4 and maintained until at least week 12 after inoculation in serum and bile. Testing before week 4 revealed undetectable or extremely low levels of antibodies, meaning the presence of much higher levels after week 4 were the result of upregulation of IgG and IgA (Matsui et al., 2003).
  • Detailed Gene Information: Click Here.